<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1328">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457570</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0509</org_study_id>
    <nct_id>NCT04457570</nct_id>
  </id_info>
  <brief_title>Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer</brief_title>
  <acronym>ONCOVID-AURA</acronym>
  <official_title>ONCOVID-AURA: Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Context:&#xD;
&#xD;
      Based on currently available data, most of national health authorities and consensus expert&#xD;
      groups have written guidelines for the management of cancer patients in the context of COVID.&#xD;
      However, the preparation of these guidelines was limited by the scarcity of solid&#xD;
      epidemiological data. For example, the experts were uncomfortable to formulate precise&#xD;
      guidelines on which anti-cancer treatment should be interrupted or replaced, on which&#xD;
      patients, and how to adapt supportive drug prescriptions.&#xD;
&#xD;
      Objectives :&#xD;
&#xD;
        -  To measure the excess risk of mortality and morbidity of patients with a history of&#xD;
           cancer among patients hospitalized for a SARS-CoV-2 infection.&#xD;
&#xD;
        -  To identify factors associated with the risk of death and morbidity among patients with&#xD;
           cancer.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Retrospective inclusion of n=200 cancer patients hospitalized for COVID and n=400 matched&#xD;
      (based on age, gender, and comorbidity) non-cancer patients hospitalized for COVID. Two&#xD;
      analyses will be performed (after the inclusion of n=100 and n=200 patients with cancer). A&#xD;
      logistic modeling of the odds ratio of death associated to the exposition factor (i.e.&#xD;
      cancer) and adjusted for the matching parameters (age, gender, comorbidities) will be&#xD;
      proposed.&#xD;
&#xD;
      We will then look for the factors (related to the patients, the cancer or the treatment) that&#xD;
      modify the odds radio.&#xD;
&#xD;
      Expected results:&#xD;
&#xD;
      The data generated will help the medical and scientific community to evaluate the increasing&#xD;
      risk of cancer patients infected by SARS-CoV-2 compared to the non-cancer population, to&#xD;
      identify patients at higher risk of severe infection, but also the anticancer treatments&#xD;
      associated with an increased risk of severe infections.&#xD;
&#xD;
      Impact:&#xD;
&#xD;
      These data will contribute to guide the future recommendations concerning cancer patient's&#xD;
      care in the context of the COVID-19 pandemic. There is a real risk that the SARS-CoV&#xD;
      epidemic, or other respiratory viruses epidemic, will become recurrent in the future. Thus,&#xD;
      it is of crucial importance for now and for the future to know which are the major factors&#xD;
      associated with severe infections&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality for SARS-CoV-2 infection</measure>
    <time_frame>30 days</time_frame>
    <description>mortality within 30 days after the hospitalization for the SARS-CoV-2 infection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID, Cancer</condition>
  <arm_group>
    <arm_group_label>exposed patients</arm_group_label>
    <description>The &quot;exposed patients&quot; are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an &quot;exposed patient&quot; if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control patients</arm_group_label>
    <description>The &quot;control patients &quot; are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mortality</intervention_name>
    <description>To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection</description>
    <arm_group_label>control patients</arm_group_label>
    <arm_group_label>exposed patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Two categories of patients will be defined: the &quot;exposed patients&quot; are patients with cancer&#xD;
        that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A&#xD;
        patient will be considered as an &quot;exposed patient&quot; if he/she had a surgical procedure or a&#xD;
        medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection.&#xD;
&#xD;
        The &quot;control patients&quot; are all of the patients without cancer that are hospitalized in one&#xD;
        of the participating centers for a SARS-CoV-2 infection.&#xD;
&#xD;
        In both cohorts, a positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection will&#xD;
        be mandatory.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  EXPOSED PATIENTS:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of solid or hematologic cancer&#xD;
&#xD;
          -  Patients who received their last anticancer treatment (surgery, systemic treatments or&#xD;
             other localized treatment) in the past 5 years before SARS-CoV-2 infection&#xD;
&#xD;
          -  Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection&#xD;
&#xD;
          -  Patients hospitalized in one of the participating centers because of the SARS-CoV-2&#xD;
             infection&#xD;
&#xD;
          -  Patients who are not opposed in participating to the ONCOVID-AURA study&#xD;
&#xD;
        CONTROL PATIENTS:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Patients who have no cancer (neither solid nor hematologic tumors) or patients who&#xD;
             received their last anticancer treatments more than five years before the SARS-CoV-2&#xD;
             infection&#xD;
&#xD;
          -  Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection&#xD;
&#xD;
          -  Patients hospitalized in one of the participating centers because of the SARS-CoV-2&#xD;
             infection&#xD;
&#xD;
          -  Patients who are not opposed in participating to the ONCOVID-AURA study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PERRON Julien, MD</last_name>
    <phone>+33 (0)4 78 86 37 75</phone>
    <email>julien.peron@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CALATTINI Sarah</last_name>
    <phone>+33 (0) 4 78 86 37 79</phone>
    <email>sara.calattini@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de lutte contre le Cancer JEAN PERRIN</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PERRON Julien, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Uniersitaire de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BAY Jacques Olivier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEROL David, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neurwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FOURNEL Pierre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de St Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Botelho-Nevers Elisabeth, PR</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

